On this page of StockholderLetter.com we present the latest annual shareholder letter from PTC THERAPEUTICS, INC. — ticker symbol PTCT. Reading current and past PTCT letters to shareholders can bring important insights into the investment thesis.
2025 ANNUAL REPORT
PTC is a global biopharmaceutical company dedicated to
the discovery, development, and commercialization of clinically
differentiated medicines for children and adults living with rare diseases
of high unmet need. We bring to market transformative therapies and
leverage our cutting-edge innovative scientific platforms as part of our
mission to provide access to best-in-class treatments.
We are focused on discovering and
developing small molecule therapies
that can deliver transformative benefits for
patients with diseases of high unmet need.
Our research efforts are focused on two
innovative scientific platforms   splicing and
inflammation and ferroptosis.
Our experienced global team strives to
provide access to our treatments for patients
with unmet medical needs worldwide. Our
strategy is to leverage our scientific expertise
and global reach to optimize value for patients
and other stakeholders.
Patients are our priority. It is essential that
their voice is part of everything we do and that
we understand their needs. We are not just
there along their journey   we are with them.
We work to transform lives.
As    One PTC,    we work together crossfunctionally and value global collaboration.
We are all working toward the same goal:
to bring much-needed treatments to
patients while still caring for each other. Our
shared purpose extends beyond PTC to the
communities around us.
PTC Therapeutics, Inc. | Annual Report 2025
A Message to
Our Shareholders
2025 was a year of strong execution and
performance across the company. We achieved
all key strategic, commercial and R&D objectives
as we continued to position the company for
future success.
The main highlight of 2025 was the initial global
approvals and launch of Sephience    (sepiapterin)
for the treatment of children and adults living with
phenylketonuria (PKU). We gained the approvals
for Sephience in the United States (U.S.), European
Union, Japan and other countries, all within several
months. The global Sephience launch got off to
a strong start with broad uptake across all age
groups and patient segments. This strong start
is a testament to the significant unmet medical
need for those affected by PKU, the differentiated
safety and efficacy profile of Sephience, and the
ability of our experienced global customer facing
teams to execute. Over the first 5.5 months of the
launch, we received prescriptions for individuals as
young as a few months of age to 80 years of age.
In addition, there was uptake across those na  ve
to previous therapies, those who have tried and
failed previous therapies and those currently on
pharmacological therapy. In the U.S., we received
more than one prescription from over 80% of
the PKU Centers of Excellence. We continue to
enjoy seeing individuals share on social media
their positive experiences with Sephience in
lowering phenylalanine (Phe) levels, enabling
diet liberalization and favorably impacting lives.
We expect the early momentum to continue into
2026 and beyond as we can continue to penetrate
deeper into the U.S. market segments and expand
the launch footprint to 20-30 countries by the end
of 2026. We expect Sephience to be a $2B+ plus
brand and provide the foundation for PTC   s nearterm growth.
The revenue from the early months of the
Sephience launch along with contributions
from our more mature brands resulted in another
year of solid revenue performance, exceeding
our revenue guidance. In addition, we delivered
another year of effective expense management
and closed the year with over $1.9B in cash. This
strong cash position enables us to continue to
support our commercial and R&D portfolios as
well as potentially engage in strategic business
development.
In 2025, we also made a number of advances in
our R&D portfolio including achieving positive
results from the Phase 2 PIVOT-HD study of
votoplam in individuals living with Huntington   s
Disease (HD) and progressing several early-stage
programs, including those from our RNA splicing
and inflammation and ferroptosis platforms.
1
   2025 marked meaningful
progress across the
company and further
positioned us to build on
our momentum in the
years to come.   
Votoplam is the leading oral disease-modifying
therapy in development for HD. Votoplam is a
highly differentiated molecule that was discovered
from PTC   s splicing platform and was partnered
with Novartis in December 2024. In May 2025,
we shared the results from the positive PIVOTHD Phase 2 study of votoplam, which met its
primary endpoint with durable dose-dependent
lowering of blood huntingtin protein levels relative
to placebo. At month 24, dose-dependent
significant effects were demonstrated relative to
a well-matched natural history cohort. We expect
an interim data readout from the PIVOT-HD longterm extension study in the first half of 2026 and
for our partner Novartis to also initiate the global
Phase 3 INVEST-HD trial of votoplam in the first half
of 2026. Based on the evidence of safety, early
clinical effect and biomarker effect, we remain
enthusiastic about the potential for votoplam to
be the first approved oral disease-modifying
therapy for HD.
In December of 2025, we held an R&D day
where we were able to detail advances we have
made in the splicing platform   including how
we have significantly expanded the universe of
potential small molecule splicing targets and built
PTCSeek      a proprietary discovery engine that
combines our splicing-centric chemical libraries,
known splicing targets and our    know-how   
built on decades of experience in splicing drug
2
development. We expect PTCSeek to facilitate
and accelerate the discovery and development
of the next wave of small molecule splicing
therapies. We already have several early-stage
programs we expect to move closer to the clinic
in 2026 including our MSH3 program for HD and
myotonic dystrophy, our sickle cell anemia/beta
thalassemia program and two neurodegenerative
target-based programs. We also have a number of
innovative programs with differentiated molecules
from our ferroptosis and inflammation platform,
including our ferroptosis Parkinson   s disease
program, our NRF-2 activation program and our
NLRP3 inflammasome program.
In conclusion, over the last two years, we have
transformed PTC into a strong, innovative,
execution-oriented global biopharmaceutical
company. With our robust global commercial
engine, including our foundational product,
Sephience, our innovative R&D platforms   
including small molecule splicing, and our strong
financial position we are well positioned for
success in 2026 and beyond.
Matthew B. Klein, M.D.
CHIEF EXECUTIVE OFFICER
PTC Therapeutics, Inc. | Annual Report 2025
2025: A Year of Focus and Execution
All key corporate objectives
were achieved
FDA, EMA, and
Japanese MHLW
approvals of
Sephience
Strong start
to Sephience
global launch
Drive revenue
and effectively
manage OpEx
Advancement of
early-stage R&D
programs
2025
3
 • shareholder letter icon 4/20/2026 Letter Continued (Full PDF)
 • stockholder letter icon 4/26/2023 PTCT Stockholder Letter
 • stockholder letter icon 4/30/2025 PTCT Stockholder Letter
 • stockholder letter icon More "Drugs & Pharmaceuticals" Category Stockholder Letters
 • Benford's Law Stocks icon PTCT Benford's Law Stock Score = 80


PTCT Shareholder/Stockholder Letter Transcript:

2025 ANNUAL REPORT

PTC is a global biopharmaceutical company dedicated to
the discovery, development, and commercialization of clinically
differentiated medicines for children and adults living with rare diseases
of high unmet need. We bring to market transformative therapies and
leverage our cutting-edge innovative scientific platforms as part of our
mission to provide access to best-in-class treatments.
We are focused on discovering and
developing small molecule therapies
that can deliver transformative benefits for
patients with diseases of high unmet need.
Our research efforts are focused on two
innovative scientific platforms   splicing and
inflammation and ferroptosis.
Our experienced global team strives to
provide access to our treatments for patients
with unmet medical needs worldwide. Our
strategy is to leverage our scientific expertise
and global reach to optimize value for patients
and other stakeholders.
Patients are our priority. It is essential that
their voice is part of everything we do and that
we understand their needs. We are not just
there along their journey   we are with them.
We work to transform lives.
As    One PTC,    we work together crossfunctionally and value global collaboration.
We are all working toward the same goal:
to bring much-needed treatments to
patients while still caring for each other. Our
shared purpose extends beyond PTC to the
communities around us.

PTC Therapeutics, Inc. | Annual Report 2025
A Message to
Our Shareholders
2025 was a year of strong execution and
performance across the company. We achieved
all key strategic, commercial and R&D objectives
as we continued to position the company for
future success.
The main highlight of 2025 was the initial global
approvals and launch of Sephience    (sepiapterin)
for the treatment of children and adults living with
phenylketonuria (PKU). We gained the approvals
for Sephience in the United States (U.S.), European
Union, Japan and other countries, all within several
months. The global Sephience launch got off to
a strong start with broad uptake across all age
groups and patient segments. This strong start
is a testament to the significant unmet medical
need for those affected by PKU, the differentiated
safety and efficacy profile of Sephience, and the
ability of our experienced global customer facing
teams to execute. Over the first 5.5 months of the
launch, we received prescriptions for individuals as
young as a few months of age to 80 years of age.
In addition, there was uptake across those na  ve
to previous therapies, those who have tried and
failed previous therapies and those currently on
pharmacological therapy. In the U.S., we received
more than one prescription from over 80% of
the PKU Centers of Excellence. We continue to
enjoy seeing individuals share on social media
their positive experiences with Sephience in
lowering phenylalanine (Phe) levels, enabling
diet liberalization and favorably impacting lives.
We expect the early momentum to continue into
2026 and beyond as we can continue to penetrate
deeper into the U.S. market segments and expand
the launch footprint to 20-30 countries by the end
of 2026. We expect Sephience to be a $2B+ plus
brand and provide the foundation for PTC   s nearterm growth.
The revenue from the early months of the
Sephience launch along with contributions
from our more mature brands resulted in another
year of solid revenue performance, exceeding
our revenue guidance. In addition, we delivered
another year of effective expense management
and closed the year with over $1.9B in cash. This
strong cash position enables us to continue to
support our commercial and R&D portfolios as
well as potentially engage in strategic business
development.
In 2025, we also made a number of advances in
our R&D portfolio including achieving positive
results from the Phase 2 PIVOT-HD study of
votoplam in individuals living with Huntington   s
Disease (HD) and progressing several early-stage
programs, including those from our RNA splicing
and inflammation and ferroptosis platforms.
1

   2025 marked meaningful
progress across the
company and further
positioned us to build on
our momentum in the
years to come.   
Votoplam is the leading oral disease-modifying
therapy in development for HD. Votoplam is a
highly differentiated molecule that was discovered
from PTC   s splicing platform and was partnered
with Novartis in December 2024. In May 2025,
we shared the results from the positive PIVOTHD Phase 2 study of votoplam, which met its
primary endpoint with durable dose-dependent
lowering of blood huntingtin protein levels relative
to placebo. At month 24, dose-dependent
significant effects were demonstrated relative to
a well-matched natural history cohort. We expect
an interim data readout from the PIVOT-HD longterm extension study in the first half of 2026 and
for our partner Novartis to also initiate the global
Phase 3 INVEST-HD trial of votoplam in the first half
of 2026. Based on the evidence of safety, early
clinical effect and biomarker effect, we remain
enthusiastic about the potential for votoplam to
be the first approved oral disease-modifying
therapy for HD.
In December of 2025, we held an R&D day
where we were able to detail advances we have
made in the splicing platform   including how
we have significantly expanded the universe of
potential small molecule splicing targets and built
PTCSeek      a proprietary discovery engine that
combines our splicing-centric chemical libraries,
known splicing targets and our    know-how   
built on decades of experience in splicing drug
2
development. We expect PTCSeek to facilitate
and accelerate the discovery and development
of the next wave of small molecule splicing
therapies. We already have several early-stage
programs we expect to move closer to the clinic
in 2026 including our MSH3 program for HD and
myotonic dystrophy, our sickle cell anemia/beta
thalassemia program and two neurodegenerative
target-based programs. We also have a number of
innovative programs with differentiated molecules
from our ferroptosis and inflammation platform,
including our ferroptosis Parkinson   s disease
program, our NRF-2 activation program and our
NLRP3 inflammasome program.
In conclusion, over the last two years, we have
transformed PTC into a strong, innovative,
execution-oriented global biopharmaceutical
company. With our robust global commercial
engine, including our foundational product,
Sephience, our innovative R&D platforms   
including small molecule splicing, and our strong
financial position we are well positioned for
success in 2026 and beyond.
Matthew B. Klein, M.D.
CHIEF EXECUTIVE OFFICER

PTC Therapeutics, Inc. | Annual Report 2025
2025: A Year of Focus and Execution
All key corporate objectives
were achieved
FDA, EMA, and
Japanese MHLW
approvals of
Sephience
Strong start
to Sephience
global launch
Drive revenue
and effectively
manage OpEx
Advancement of
early-stage R&D
programs
2025
3



shareholder letter icon 4/20/2026 Letter Continued (Full PDF)
 

PTCT Stockholder/Shareholder Letter (PTC THERAPEUTICS, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2026, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.